Pacira BioSciences Inc (NASDAQ: PCRX)’s stock price has decreased by -0.16 compared to its previous closing price of 24.91. However, the company has seen a -5.97% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-08 that Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Susan Mesco – Head of Investor Relations Frank Lee – Chief Executive Officer Jonathan Slonin – Chief Medical Officer Shawn Cross – Chief Financial Officer Brendan Teehan – Chief Commercial Officer Conference Call Participants Anish Nikhanj – RBC Capital Markets Gary Nachman – Raymond James Hardik Parikh – JPMorgan Serge Belanger – Needham Operator Good day, and thank you for standing by. Welcome to the First Quarter 2025 Pacira BioSciences Earnings Conference Call.
Is It Worth Investing in Pacira BioSciences Inc (NASDAQ: PCRX) Right Now?
PCRX has 36-month beta value of 0.54. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for PCRX is 44.25M, and currently, short sellers hold a 13.70% ratio of that float. The average trading volume of PCRX on May 09, 2025 was 885.64K shares.
PCRX’s Market Performance
PCRX stock saw a decrease of -5.97% in the past week, with a monthly decline of -3.75% and a quarterly a decrease of -4.71%. The volatility ratio for the week is 4.02%, and the volatility levels for the last 30 days are 5.19% for Pacira BioSciences Inc (PCRX). The simple moving average for the last 20 days is -2.84% for PCRX stock, with a simple moving average of 23.78% for the last 200 days.
Analysts’ Opinion of PCRX
Many brokerage firms have already submitted their reports for PCRX stocks, with Truist repeating the rating for PCRX by listing it as a “Hold.” The predicted price for PCRX in the upcoming period, according to Truist is $25 based on the research report published on January 30, 2025 of the current year 2025.
Truist, on the other hand, stated in their research note that they expect to see PCRX reach a price target of $8, previously predicting the price at $30. The rating they have provided for PCRX stocks is “Sell” according to the report published on August 13th, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to PCRX, setting the target price at $14 in the report published on August 12th of the previous year.
PCRX Trading at 1.08% from the 50-Day Moving Average
After a stumble in the market that brought PCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.47% of loss for the given period.
Volatility was left at 5.19%, however, over the last 30 days, the volatility rate increased by 4.02%, as shares surge +3.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.19% lower at present.
During the last 5 trading sessions, PCRX fell by -7.11%, which changed the moving average for the period of 200-days by +22.97% in comparison to the 20-day moving average, which settled at $25.58. In addition, Pacira BioSciences Inc saw 32.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCRX starting from GAUGLER DARYL, who proposed sale 500 shares at the price of $23.25 back on Mar 06 ’25. After this action, GAUGLER DARYL now owns shares of Pacira BioSciences Inc, valued at $11,625 using the latest closing price.
SLONIN JONATHAN, the Chief Medical Officer of Pacira BioSciences Inc, sale 879 shares at $18.40 during a trade that took place back on Jan 06 ’25, which means that SLONIN JONATHAN is holding 93,444 shares at $16,174 based on the most recent closing price.
Stock Fundamentals for PCRX
Current profitability levels for the company are sitting at:
- -0.1 for the present operating margin
- 0.72 for the gross margin
The net margin for Pacira BioSciences Inc stands at -0.14. The total capital return value is set at -0.06. Equity return is now at value -12.08, with -6.37 for asset returns.
Based on Pacira BioSciences Inc (PCRX), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 0.82. The interest coverage ratio of the stock is -4.81.
Currently, EBITDA for the company is 32.25 million with net debt to EBITDA at 17.19. When we switch over and look at the enterprise to sales, we see a ratio of 2.19. The receivables turnover for the company is 6.19for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.40.
Conclusion
To put it simply, Pacira BioSciences Inc (PCRX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
